A humanized anti-VLA-4 mAb (‘Natalizumab’) that managed to reach the clinic was found effective in relapsing-remitting multiple sclerosis,208,209 and was approved for this indication. The most likely mode of action is inhibition of crossing the blood–brain barrier by activated T cells and dendritic cells.